Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: A multi-center randomized controlled trial. Issue 6 (December 2021)

• Record Type: Journal Article
• Authors: Chen, Xue; Zhao, Songqing; Hsue, Cunyi; Dai, Xia; Liu, Lin; Miller, Joshua D.; Fang, Zhaohui; Feng, Jitao; Huang, Yong; Wang, Xindong; Lou, Qingqing
• Is Part Of: Primary care diabetes. Volume 15:Issue 6(2021)
• Page Start: 1063
• Page End: 1070
• Publication Date: 2021-12
• Subjects: Prediabetes -- Aerobic training -- Resistance training -- Cardiovascular disease risk; Diabetes -- Periodicals; 616.462
• DOI: 10.1016/j.pcd.2021.08.013
• Languages: English
• ISSNs: 1751-9918

Abstract

Highlights: Aerobic training reduced The Chinese 10-year ischemic cardiovascular disease (ICVD) risk and FRS cardiovascular disease risk in patients with prediabetes. Resistance training appears to decrease 10-year ICVD risk in prediabetes patients. Aerobic training and resistance training both reduce HbA1c. Abstract: Aims: Aerobic training (AT) and resistance training (RT) can reduce blood glucose and type 2 diabetes risk, and increase muscle mass for prediabetes patients. However, the impact of long-term AT and RT on cardiovascular disease (CVD) risk remains unclear. The purpose of this study was to investigate the impact of AT and RT on CVD risk reduction in prediabetes patients. Materials and methods: 248 prediabetes patients were enrolled in this multi-center randomized controlled trial (RCT). Patients were randomly divided into 3 groups: RT (n = 82), aerobic training (AT (n = 83)), and control group (n = 83). Participants in RT and AT groups had moderate RT or AT 3 times a week (150 min/week) under supervision in 3 research centers for 24 months. Primary outcome was CVD risk measured by Framingham Risk Score (FRS) and The Chinese 10-year ischemic cardiovascular disease (ICVD) risk assessment tool. Secondary outcomes included in HOMA2-IR, HbA1c, blood pressure and serum lipid profile. Results: Both RT and AT groups experienced a significant reduction in HOMA2-IR, HbA1c, LDL-C, TC, SBP, and DBP at the end of 12 and 24 months. Compared to the control group, Both RT and AT groups had significant reduction of the Chinese 10-year ICVD risk (P < 0.05), but FRS CVD risk declined significantly only in the AT group (all P < 0.05). Although FRS CVD risk decreased more in the RT group than in the control group, the difference was not statistically significant. After adjusting for age, gender, statin use, BMI, and WHR, in COX's proportional hazard model, RT (HR = 0.419, P = 0.037) and AT (HR = 0.310, P = 0.026) were protective factors for CVD risk in prediabetes patients. 24-month RT and AT decreased respectively 58.1% and 69.0% of CVD risk (10-year ICVD risk assessment) in prediabetes patients. Conclusions: This study demonstrated that 24-month moderate AT reduces the Chinese 10-year ICVD risk and FRS CVD risk in prediabetes patients. RT groups had significant reduction of CVD risk (10-year ICVD risk assessment) in prediabetes patients. Trial registration: Clinical trial registration number: NCT 02561377. Date of registration: 24/09/2015.